drugset

drugset / Trial / NCT01023282

Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

NCT01023282 ↗

Phase 1 Completed 22 enrolled NeuroSearch A/S

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.

Timeline

Start: 2009-11
Primary completion: 2011-04
Completion: 2011-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ORDOPIDINE	Small molecule	75 mg	—

Indications